{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:38:47Z","timestamp":1788406727273,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.neuropharm.2024.109909","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T17:15:41Z","timestamp":1710522941000},"page":"109909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Neuro-modulatory impact of felodipine against experimentally-induced Parkinson's disease: Possible contribution of PINK1-Parkin mitophagy pathway"],"prefix":"10.1016","volume":"250","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7674-4263","authenticated-orcid":false,"given":"Hadeer O.","family":"Abou-Hany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Sherbiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Elshaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neuropharm.2024.109909_bib1","first-page":"863","article-title":"Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of \u03b1-synuclein and parkin levels in rotenone-induced Parkinson\u2019s disease in rats","volume":"30","author":"Ahmed","year":"2022","journal-title":"Saudi pharmaceutical journal\u202f: SPJ\u202f: the official publication of the Saudi Pharmaceutical Society,"},{"key":"10.1016\/j.neuropharm.2024.109909_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neubiorev.2016.03.016","article-title":"Animal behavioral assessments in current research of Parkinson's disease","volume":"65","author":"Asakawa","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2024.109909_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00099-20","article-title":"The molecular mechanisms regulating the KEAP1-NRF2 pathway","volume":"40","author":"Baird","year":"2020","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2024.109909_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fnagi.2020.00068","article-title":"Nuclear factor-\u03baB dysregulation and \u03b1-synuclein pathology: critical interplay in the pathogenesis of Parkinson's disease","volume":"12","author":"Bellucci","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fnana.2015.00091","article-title":"Oxidative stress and Parkinson's disease","volume":"9","author":"Blesa","year":"2015","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuropharm.2024.109909_bib6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/JPD-150642","article-title":"The synaptic function of \u03b1-synuclein","volume":"5","author":"Burr\u00e9","year":"2015","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2024.109909_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/ph14060573","article-title":"Repurposing drugs to treat heart and brain illness","volume":"14","author":"Cantrell","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neuropharm.2024.109909_bib8","first-page":"2610","article-title":"Measuring the strength of mice","volume":"76","author":"Deacon","year":"2013","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.neuropharm.2024.109909_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2020.102216","article-title":"Targeting mitochondrial calcium pathways as a potential treatment against Parkinson's disease","volume":"89","author":"Dey","year":"2020","journal-title":"Cell Calcium"},{"key":"10.1016\/j.neuropharm.2024.109909_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/JPD-130230","article-title":"The role of oxidative stress in Parkinson's disease","volume":"3","author":"Dias","year":"2013","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2024.109909_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1186\/1756-0500-5-513","article-title":"A simple protocol for the subcellular fractionation of skeletal muscle cells and tissue","volume":"5","author":"Dimauro","year":"2012","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.neuropharm.2024.109909_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.00084","article-title":"Metformin protects from rotenone\u2013induced nigrostriatal neuronal death in adult mice by activating AMPK-FOXO3 signaling and mitigation of angiogenesis","volume":"13","author":"EL-Ghaiesh","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00612","article-title":"Parkinson's disease: biomarkers, treatment, and risk factors","volume":"12","author":"Emamzadeh","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/cdd.2014.150","article-title":"Oxidative stress and autophagy: the clash between damage and metabolic needs","volume":"22","author":"Filomeni","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.neuropharm.2024.109909_bib15","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1523\/JNEUROSCI.22-03-00782.2002","article-title":"Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons","volume":"22","author":"Gao","year":"2002","journal-title":"the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.neuropharm.2024.109909_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13024-020-00367-7","article-title":"PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease","volume":"15","author":"Ge","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2024.109909_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease","volume":"51","author":"Gibb","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2024.109909_bib18","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/nprot.2007.304","article-title":"Processing tissue and cells for transmission electron microscopy in diagnostic pathology and research","volume":"2","author":"Graham","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2024.109909_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2021.132982","article-title":"Rotenone impairs learning and memory in mice through microglia-mediated blood brain barrier disruption and neuronal apoptosis","volume":"291","author":"Guo","year":"2022","journal-title":"Chemosphere"},{"key":"10.1016\/j.neuropharm.2024.109909_bib20","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1471-4159.2005.03493.x","article-title":"The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy","volume":"95","author":"H\u00f6glinger","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2024.109909_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cotox.2016.10.002","article-title":"The multifaceted role of Nrf2 in mitochondrial function","volume":"1","author":"Holmstr\u00f6m","year":"2016","journal-title":"Current opinion in toxicology"},{"key":"10.1016\/j.neuropharm.2024.109909_bib22","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jmb.2020.01.037","article-title":"Autophagy in Parkinson's disease","volume":"432","author":"Hou","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2024.109909_bib23","article-title":"Anti-neuroinflammatory effects of the calcium channel blocker nicardipine on microglial cells: implications for neuroprotection","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2024.109909_bib24","article-title":"Moxibustion protects dopaminergic neurons in Parkinson's disease through antiferroptosis","volume":"2021","author":"Huang","year":"2021","journal-title":"Evid. base Compl. Alternative Med."},{"key":"10.1016\/j.neuropharm.2024.109909_bib25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.biopha.2018.11.133","article-title":"Targeting Nrf2\/HO-1 signaling by crocin: role in attenuation of AA-induced ulcerative colitis in rats","volume":"110","author":"Khodir","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2024.109909_bib26","article-title":"L-type Ca2+ channel inhibition rescues the LPS-induced neuroinflammatory response and impairments in spatial memory and dendritic spine formation","volume":"23","author":"Kim","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/gtc.12066","article-title":"The principal <scp>PINK1<\/scp> and Parkin cellular events triggered in response to dissipation of mitochondrial membrane potential occur in primary neurons","volume":"18","author":"Koyano","year":"2013","journal-title":"Gene Cell."},{"key":"10.1016\/j.neuropharm.2024.109909_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12031-012-9814-5","article-title":"Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson's disease","volume":"48","author":"Li","year":"2012","journal-title":"Journal of molecular neuroscience"},{"key":"10.1016\/j.neuropharm.2024.109909_bib29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.expneurol.2013.01.001","article-title":"Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity","volume":"247","author":"Liu","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2024.109909_bib30","article-title":"Nitric oxide, iron and neurodegeneration","volume":"13","author":"Liu","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib31","first-page":"615","article-title":"Mitochondria-mediated damage to dopaminergic neurons in Parkinson's disease","volume":"41","author":"Liu","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.neuropharm.2024.109909_bib32","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrn983","article-title":"Pathogenesis of Parkinson's disease: dopamine, vesicles and \u03b1-synuclein","volume":"3","author":"Lotharius","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib33","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1021\/acschemneuro.8b00516","article-title":"SQSTM1\/p62: a potential target for neurodegenerative disease","volume":"10","author":"Ma","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib34","doi-asserted-by":"crossref","DOI":"10.4081\/ejh.2016.2639","article-title":"Histological and histochemical methods - theory and practice","volume":"60","author":"Malatesta","year":"2016","journal-title":"Eur. J. Histochem."},{"key":"10.1016\/j.neuropharm.2024.109909_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semcdb.2015.03.005","article-title":"Autophagy in neurodegenerative diseases: from pathogenic dysfunction to therapeutic modulation","volume":"40","author":"Martinez-Vicente","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2024.109909_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/1759091418775562","article-title":"Neuroprotective role of astroglia in Parkinson disease by reducing oxidative stress through dopamine-induced activation of pentose-phosphate pathway","volume":"10","author":"Mashima","year":"2018","journal-title":"ASN Neuro"},{"key":"10.1016\/j.neuropharm.2024.109909_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41531-021-00273-9","article-title":"Lewy body disease or diseases with Lewy bodies?","volume":"8","author":"Men\u0161\u00edkov\u00e1","year":"2022","journal-title":"npj Parkinson's Disease"},{"key":"10.1016\/j.neuropharm.2024.109909_bib38","doi-asserted-by":"crossref","first-page":"s32","DOI":"10.1007\/s100720300035","article-title":"Autonomic dysfunction in Parkinson's disease","volume":"24","author":"Micieli","year":"2003","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12993-020-00171-9","article-title":"Forced exercise activates the NrF2 pathway in the striatum and ameliorates motor and behavioral manifestations of Parkinson's disease in rotenone-treated rats","volume":"16","author":"Monir","year":"2020","journal-title":"Behav. Brain Funct."},{"key":"10.1016\/j.neuropharm.2024.109909_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jneumeth.2006.06.001","article-title":"Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model","volume":"158","author":"Monville","year":"2006","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2024.109909_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13024-017-0154-3","article-title":"Therapeutic potential of autophagy-enhancing agents in Parkinson's disease","volume":"12","author":"Moors","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2024.109909_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.636506","article-title":"Understanding the multiple role of mitochondria in Parkinson's disease and related disorders: lesson from genetics and protein\u2013interaction network","volume":"9","author":"Nicoletti","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2024.109909_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1232241","article-title":"An update on the bridging factors connecting autophagy and Nrf2 antioxidant pathway","volume":"11","author":"Ning","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2024.109909_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060378","article-title":"Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function","volume":"8","author":"Oaks","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2024.109909_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries\/territories from 1990 to 2019","volume":"9","author":"Ou","year":"2021","journal-title":"Front. Public Health"},{"key":"10.1016\/j.neuropharm.2024.109909_bib46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pbb.2016.04.001","article-title":"Effect of the C-terminal domain of the heavy chain of tetanus toxin on dyskinesia caused by levodopa in 6-hydroxydopamine-lesioned rats","volume":"145","author":"Palafox-S\u00e1nchez","year":"2016","journal-title":"Pharmacology, biochemistry, and behavior"},{"key":"10.1016\/j.neuropharm.2024.109909_bib47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12640-018-9957-4","article-title":"Mutual antagonism of PINK1\/parkin and PGC-1\u03b1 contributes to maintenance of mitochondrial homeostasis in rotenone-induced neurotoxicity","volume":"35","author":"Peng","year":"2019","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2024.109909_bib48","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.tox.2013.11.003","article-title":"Rotenone and paraquat perturb dopamine metabolism: a computational analysis of pesticide toxicity","volume":"315","author":"Qi","year":"2014","journal-title":"Toxicology"},{"key":"10.1016\/j.neuropharm.2024.109909_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s40478-020-01062-w","article-title":"PINK1\/PARKIN signalling in neurodegeneration and neuroinflammation","volume":"8","author":"Quinn","year":"2020","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/j.neuropharm.2024.109909_bib50","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00702-022-02488-3","article-title":"From the tyrosine hydroxylase hypothesis of Parkinson's disease to modern strategies: a short historical overview","volume":"129","author":"Rausch","year":"2022","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2024.109909_bib51","article-title":"Upstream deregulation of calcium signaling in Parkinson's disease","volume":"7","author":"Rivero-R\u00edos","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib52","doi-asserted-by":"crossref","DOI":"10.21037\/aes-21-31","article-title":"A revisit to staining reagents for neuronal tissues","volume":"7","author":"Rosario","year":"2022","journal-title":"Annals of eye science"},{"key":"10.1016\/j.neuropharm.2024.109909_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.787258","article-title":"A perspective on Nrf2 signaling pathway for neuroinflammation: a potential therapeutic target in alzheimer's and Parkinson's diseases","volume":"15","author":"Saha","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107900","article-title":"Neuroprotective effect of crocin against rotenone-induced Parkinson's disease in rats: interplay between PI3K\/Akt\/mTOR signaling pathway and enhanced expression of miRNA-7 and miRNA-221","volume":"164","author":"Salama","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109909_bib55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/002215540205000111","article-title":"Improved detection of substantia nigra pathology in alzheimer's disease","volume":"50","author":"Schneider","year":"2002","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.neuropharm.2024.109909_bib56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5483\/BMBRep.2020.53.1.283","article-title":"The central regulator p62 between ubiquitin proteasome system and autophagy and its role in the mitophagy and Parkinson's disease","volume":"53","author":"Shin","year":"2020","journal-title":"BMB reports"},{"key":"10.1016\/j.neuropharm.2024.109909_bib57","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/s41467-019-09494-2","article-title":"Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing","volume":"10","author":"Siddiqi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2024.109909_bib58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s13238-015-0230-9","article-title":"Parkin promotes proteasomal degradation of p62: implication of selective vulnerability of neuronal cells in the pathogenesis of Parkinson's disease","volume":"7","author":"Song","year":"2016","journal-title":"Protein Cell"},{"key":"10.1016\/j.neuropharm.2024.109909_bib59","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1089\/ars.2015.6539","article-title":"TCF11\/Nrf1-Mediated induction of proteasome expression prevents cytotoxicity by rotenone","volume":"25","author":"Sotzny","year":"2016","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.neuropharm.2024.109909_bib60","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3109\/03639045.2013.819885","article-title":"Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro","volume":"40","author":"Surya Sandeep","year":"2014","journal-title":"Drug development and industrial pharmacy"},{"key":"10.1016\/j.neuropharm.2024.109909_bib61","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1745-7254.2008.00843.x","article-title":"Felodipine attenuates vascular inflammation in a fructose-induced rat model of metabolic syndrome via the inhibition of NF-\u03baB activation","volume":"29","author":"Tan","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2024.109909_bib62","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3389\/fneur.2018.00860","article-title":"Outside in: unraveling the role of neuroinflammation in the progression of Parkinson's disease","volume":"9","author":"Troncoso-Escudero","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2024.109909_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117412","article-title":"Calcium Channel blockers are associated with reduced risk of Parkinson's disease in patients with hypertension: a population-based retrospective cohort study","volume":"424","author":"Tseng","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.581191","article-title":"Chemically induced models of Parkinson's disease: history and perspectives for the involvement of ferroptosis","volume":"14","author":"Wen","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109909_bib65","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbr.2014.11.002","article-title":"The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings","volume":"279","author":"Wrangel","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2024.109909_bib66","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2119\/2008-00024.Xing","article-title":"Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats","volume":"14","author":"Xing","year":"2008","journal-title":"Molecular medicine (Cambridge, Mass"},{"key":"10.1016\/j.neuropharm.2024.109909_bib67","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s11064-013-1055-7","article-title":"Rotenone could activate microglia through NF\u03baB associated pathway","volume":"38","author":"Yuan","year":"2013","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2024.109909_bib68","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.toxlet.2014.11.029","article-title":"The molecular mechanism of rotenone-induced \u03b1-synuclein aggregation: emphasizing the role of the calcium\/GSK3\u03b2 pathway","volume":"233","author":"Yuan","year":"2015","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.neuropharm.2024.109909_bib69","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1242\/dmm.028738","article-title":"The role of Ca(2+) signaling in Parkinson's disease","volume":"10","author":"Zaichick","year":"2017","journal-title":"Disease Models & Mechanisms"},{"key":"10.1016\/j.neuropharm.2024.109909_bib70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pharmthera.2005.05.007","article-title":"Role of nitric oxide in Parkinson's disease","volume":"109","author":"Zhang","year":"2006","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.109909_bib71","doi-asserted-by":"crossref","first-page":"9968","DOI":"10.1038\/s41598-017-07442-y","article-title":"Therapeutic effects of baicalein on rotenone-induced Parkinson's disease through protecting mitochondrial function and biogenesis","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2024.109909_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00809","article-title":"Tau pathology in Parkinson's disease","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2024.109909_bib73","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.brainres.2016.11.020","article-title":"Subcutaneous rotenone rat model of Parkinson's disease: dose exploration study","volume":"1655","author":"Zhang","year":"2017","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.109909_bib74","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuint.2018.04.013","article-title":"Mitochondrial alterations in Parkinson's disease human samples and cellular models","volume":"118","author":"Zilocchi","year":"2018","journal-title":"Neurochem. Int."}],"updated-by":[{"DOI":"10.1016\/j.neuropharm.2024.110053","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000}}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824000789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824000789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T17:52:47Z","timestamp":1712080367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824000789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":74,"alternative-id":["S0028390824000789"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109909","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.neuropharm.2024.110053","asserted-by":"object"}]},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuro-modulatory impact of felodipine against experimentally-induced Parkinson's disease: Possible contribution of PINK1-Parkin mitophagy pathway","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109909"}}